Video: RA and Cancer: Myth or Reality? Dr. Jonathan Kay ( @RheumKay ) Dr. Kay reviewed highlights from the "Oncorheumatology: the crossroads of cancer and musculoskeletal diseases" scientific session including abstract OP0187, presented at #EULAR2021. https://t.co/KaLEZ67L5S https://t.co/6MHXyffO2W

• https://bit.ly/3zaruJa

Video: The Future of Treatment of RA-ILD: Dr. David Liew ( @drdavidliew ) Dr. David Liew reviews abstract OP0124 presented at #EULAR2021 https://t.co/0dqBPRiwjA https://t.co/XR7cQhPVRw

• https://bit.ly/3w1PGLE

RA after 70: Too Old for bioDMARDs? by Dr. Aurelie Najm #EULAR2021 In RA, the two most common peaks of incidence are 30s and 50s; however a significant % of patients in 70s present with active RA -of early or later onset- and require adapted treatment. https://t.co/w6rxT0FmlP https://t.co/fnvSQcu0Fl

• https://bit.ly/2T0m9n2

Video: Difficult to Treat RA: Look out for Comorbidities: Dr. Aurelie Najm #EULAR2021 https://t.co/71Kx0HmmDm https://t.co/iu2p2EXNof

• https://bit.ly/3pyAB1W

Clive Kelly presents data from INBUILD on nintedanib in progressive fibrosing RA-ILD over 52 weeks FVC decline -82.6 (41.3) mL in nintedanib vs -199.3 (36.2) mL in placebo (p=0.037) @RheumNow #EULAR2021 Abstr#OP0124 https://t.co/MZwzNoq6LC

⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX) -Tx . (TP)1: SEC 75/100 mg till wk 12 -TP2: cont SEC or switch to PBO till wk 104 ⭐️SEC efficacious on JIA ACR30/70 ⭐️74% w/ resolution of enthes ⭐️Median T2flare in PBO in TP2 = 453d LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6

What to tell pts about diet? *⃣Nutrition plays a role in inflammation in RMD & co-morbidities. What you eat matters! *⃣ LImit salt, replace w/ herbs *⃣ Consume low glycemic index foods. Soda ⬆️risk of RA in women *⃣⬆️omega-3 ⬇️omega-6 (dairy, eggs) #EULAR2021 @Rheumnow